Analytical and field evaluation of the Biocentric Generic HCV Assay on open polyvalent PCR platforms in France and Cambodia

Treatment options to achieve definitive cure of chronic hepatitis C infection have been recently revolutionised with the second generation of direct-acting antivirals (DAAs). The HCV global strategy launched in 2016 by World Health Organisation (WHO) aimed to eliminate HCV epidemic by 2030[1]. Reducing the burden of HCV in low- and middle-incomes countries necessitates ongoing efforts to improve access to treatment and diagnosis. The expansion in affordable DAAs availability, creates an urgent need for scale-up and strengthening of the laboratory equipment required for initiation and monitoring of HCV treatment.

Source: Journal of Clinical Virology - September 17, 2018 Category: Virology Authors: J Nouhin, K Bollore, J Castera-Guy, S Prak, S Heng, A Kerleguer, PA Rubbo, F Rouet, E Tuaillon Source Type: research